Technical Notes

Acute feeding studies

Hypophagic potential: Acute Feeding Studies with novel drugs in mice and rats. Rapid assessment, various routes, up to 7-day evaluation. Discover ED50 values & pharmacokinetics. Advance drug development

Adriamycin-induced model of focal segmental glomerulosclerosis (FSGS) and fibrosis

Explore the Adriamycin-induced Model of Focal Segmental Glomerulosclerosis (FSGS) and Fibrosis. Discover how this rodent model mimics human proteinuric kidney disease, offering quick induction of renal injury and a customizable study design for prevention...

Anti-GBM Model of nephrotoxic nephritis and inflammation

Revolutionary GN research: anti-GBM rodent model mimics human GN, showcasing rapid inflammation, severe proteinuria & effective treatments.

Aqueous solubility – turbidimetric / kinetic – thermodynamic

Discover the importance of aqueous solubility in drug discovery and development. Overcome low solubility obstacles with our kinetic and thermodynamic solubility assays. Improve drug absorption and formulation. Explore our DMPK/ADME capabilities now!

Assessment of Energy Expenditure

The mechanisms underlying the reduction in body weight produced by novel anti-obesity drugs should always be investigated by measuring the effects of the compound on both sides of the energy equation balance. Energy Expenditure...

Assessment of gastric emptying rate to explore mechanisms of satiety and reduced food intake

Explore the mechanisms of satiety and reduced food intake through gastric emptying rate assessment. Our direct and indirect models offer insights into drug effects. Validate with clinical opioid agonist loperamide.

Behavioural aspects of feeding to explore specificity of effects on food intake

Discovering specific effects on food intake: Satiation profiling and pica assessment help identify potential anti-obesity agents.

Binge Eating Disorder

Sygnature has successfully developed and validated a new rat model of binge-eating disorder. Rats are given free access to normal rat diet and irregular access to chocolate for limited periods (2 h). After 3-4...

Blood Plasma Partitioning

Learn about the impact of drug binding to red blood cells (RBC) and plasma proteins on pharmacokinetics. Discover how RBC binding can affect drug concentration, pharmacological action, and potential toxicity. Understand the importance of...

Body composition analysis to determine specificity of weight loss

Explore body composition analysis for weight loss assessment in mice, differentiating fat loss from harmful water and protein reduction. Methods include DEXA and gold-standard techniques for valuable insights into interventions and drug effects.

Caco-2 Permeability

The human colon epithelial cancer cell line, Caco-2, is used as a model of human intestinal absorption of drugs. This model is suitable to test compound suitability for oral dosing, predict intestinal permeability and...

Chemical Stability

Explore drug stability assessment under physiological conditions using Sygnature's chemical stability assay. Learn about its significance in understanding molecule lability and potential impacts on biological data and pharmacokinetics.

CYP Induction (mRNA) / HepaRG

Uncover CYP induction's impact on drug interactions & metabolism. Stay FDA-compliant with CYP1A2, CYP2B6, & CYP3A4 investigations.

Cytotoxicity testing

Discover precise cytotoxicity testing with Sygnature's Cell Viability assay. Efficient, innovative, and informed drug safety assessment.

Dietary-Induced obese (DIO) mice and rat model

Explore our ready-to-use Dietary-Induced Obese (DIO) mouse and rat models, perfect for assessing weight loss interventions and testing novel treatments. Our DIO mouse model boasts stable weight, significant adiposity, insulin resistance, lipid deposition, and...

Drug Discrimination

Explore Drug Discrimination: Rat interoceptive cues distinguish CNS drugs. Vital in CNS-active compound assessment for psychoactive effects.

Early Assessment of Abuse Potential

Sygnature provides a variety of models to compare the pharmacological profiles of novel drugs with known drugs of abuse. These models enable the early assessment of abuse potential. Locomotor activity All drugs of abuse...

Genetic models of insulin resistance and type 2 diabetes

Explore our genetic models of insulin resistance and type 2 diabetes. Our expertise lies in working with animal models predisposed to these conditions, such as ob/ob mice, db/db mice, and Zucker fatty rats. Discover...

Glucocorticoid-induced model of insulin resistance

Explore our rapid model of glucocorticoid-induced insulin resistance, ideal for testing antidiabetic potential of new drugs. Witness the inhibitory effects of mifepristone and CORT125134 on insulin resistance and hyperglycaemia in rats.

H-FFC CCl4 model of severe fibrosis and NASH

Explore our advanced H-FFC CCl4 model, a cutting-edge representation of severe fibrosis and NASH (non-alcoholic steatohepatitis). Sygnature Discovery offers a unique platform for evaluating potential therapies targeting both NASH and fibrosis. Our model mimics...

H-FFC mouse model of NASH and fibrosis

Non-alcoholic steatohepatitis (NASH) and liver fibrosis are associated with an increased risk of developing hepatocellular carcinoma and ultimately end-stage liver disease. In the clinic NASH is often accompanied with metabolic syndrome, specifically obesity, type...

Hepatocyte Metabolic Stability

The liver is the major site of drug metabolism in the body, with well over 50% of marketed drugs eliminated via hepatic mediated metabolism. Hence, measurement of the rate of clearance and the identity...

In vivo PK / Pharmacokinetic studies

Explore In Vivo Pharmacokinetic (PK) Studies: Learn about drug absorption, distribution, metabolism, and elimination (ADME). Discover the key parameters - AUC, Cmax, t½, Vss, and clearance - in early-stage drug development. Uncover insights into...

Intracerebral Microdialysis

Discover precise insights into brain function with Sygnature's premier intracerebral microdialysis services for rats and mice. With over two decades of expertise, our dedicated team customizes studies to your specific requirements, utilising cutting-edge UHPLC...

LogD (Micro Shake-Flask)

Optimise drug design: Measure lipophilicity with LogD (Micro Shake-Flask) for better ADME profiles & reduced drug interactions.

MDCK-WT/MDR1 Permeability

Wild-type MDCK (Madin-Darby canine kidney) cells, when transfected with either the Multidrug Resistance gene-1 (MDR1; P-gp) or Breast Cancer Resistance gene (BCRP), are used as a model of brain penetration and to understand the...

Metabolite Profiling

Drug Metabolism Insights: Explore Metabolite Profiling with Sygnature Discovery. Discover how liver metabolism influences drug clearance, and how Sygnature's specialized assays, utilizing hepatocytes, microsomes, and more, can guide your drug discovery project. Predict in...

Microsomal Clearance and Stability

Discover the significance of hepatic drug metabolism through microsomal clearance studies. Sygnature offers NADPH-based Phase I assays and combined Phase I/Phase II assays for comprehensive metabolism insights. Gain compound ranking and predict in vivo...

P450 / CYP Inhibition

Discover P450/CYP inhibition & drug interactions. Assess CYP isoforms, predict co-administered drug risks. Reliable screening with Sygnature.

Parallel Artificial Membrane Permeability Assay (PAMPA)

Enhance drug development using PAMPA assay for permeability assessment. Rapid, accurate, and high-throughput method. Sygnature's advanced approach with Corning's pre-coated plate system. LC-MS/MS readouts and precise calibration curve ensure reliable results. Caffeine and Famotidine...